These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 16444746

  • 1. Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.
    Morotti A, Cilloni D, Messa F, Arruga F, Defilippi I, Carturan S, Catalano R, Rosso V, Chiarenza A, Pilatrino C, Guerrasio A, Taulli R, Bracco E, Pautasso M, Baraban D, Gottardi E, Saglio G.
    Cancer; 2006 Mar 01; 106(5):1188-96. PubMed ID: 16444746
    [Abstract] [Full Text] [Related]

  • 2. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [Abstract] [Full Text] [Related]

  • 3. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
    Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K.
    Cancer Res; 2003 Aug 15; 63(16):5126-35. PubMed ID: 12941844
    [Abstract] [Full Text] [Related]

  • 4. The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
    Rahmani M, Nguyen TK, Dent P, Grant S.
    Mol Pharmacol; 2007 Sep 15; 72(3):788-95. PubMed ID: 17595328
    [Abstract] [Full Text] [Related]

  • 5. Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines.
    Desplat V, Belloc F, Lagarde V, Boyer C, Melo JV, Reiffers J, Praloran V, Mahon FX.
    Cancer; 2005 Jan 01; 103(1):102-10. PubMed ID: 15558795
    [Abstract] [Full Text] [Related]

  • 6. Bcr-Abl-independent imatinib-resistant K562 cells show aberrant protein acetylation and increased sensitivity to histone deacetylase inhibitors.
    Lee SM, Bae JH, Kim MJ, Lee HS, Lee MK, Chung BS, Kim DW, Kang CD, Kim SH.
    J Pharmacol Exp Ther; 2007 Sep 01; 322(3):1084-92. PubMed ID: 17569822
    [Abstract] [Full Text] [Related]

  • 7. STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
    Greene LM, Kelly L, Onnis V, Campiani G, Lawler M, Williams DC, Zisterer DM.
    J Pharmacol Exp Ther; 2007 Apr 01; 321(1):288-97. PubMed ID: 17202400
    [Abstract] [Full Text] [Related]

  • 8. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P, Jia T, Demehri S, Härtel N, de Vries P, Bonham L, Hollenback D, Singer JW, Melo JV, Druker BJ, Deininger MW.
    Clin Cancer Res; 2006 Nov 01; 12(21):6540-6. PubMed ID: 17085669
    [Abstract] [Full Text] [Related]

  • 9. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B, Schumacher P, Petzer A, Hoflehner E, Haun M, Wolf AM, Nachbaur D, Gastl G.
    Eur J Haematol; 2009 Jul 01; 83(1):48-56. PubMed ID: 19226363
    [Abstract] [Full Text] [Related]

  • 10. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS, Liu DS, Dai CW, Li RJ.
    Am J Hematol; 2006 Apr 01; 81(4):242-55. PubMed ID: 16550520
    [Abstract] [Full Text] [Related]

  • 11. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors.
    Brieger A, Boehrer S, Schaaf S, Nowak D, Ruthardt M, Kim SZ, Atadja P, Hoelzer D, Mitrou PS, Weidmann E, Chow KU.
    Biochem Pharmacol; 2004 Jul 01; 68(1):85-93. PubMed ID: 15183120
    [Abstract] [Full Text] [Related]

  • 12. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ, Kim MJ, Kim HB, Kang CD, Kim SH.
    Biochem J; 2009 Apr 28; 420(1):73-81. PubMed ID: 19203346
    [Abstract] [Full Text] [Related]

  • 13. Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.
    Lavallard VJ, Pradelli LA, Paul A, Bénéteau M, Jacquel A, Auberger P, Ricci JE.
    Cancer Res; 2009 Apr 01; 69(7):3013-20. PubMed ID: 19318579
    [Abstract] [Full Text] [Related]

  • 14. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
    Wang W, Zhang J, Li Y, Yang X, He Y, Li T, Ren F, Zhang J, Lin R.
    Cancer Lett; 2015 Jan 28; 356(2 Pt B):791-9. PubMed ID: 25449787
    [Abstract] [Full Text] [Related]

  • 15. N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
    Rakshit S, Bagchi J, Mandal L, Paul K, Ganguly D, Bhattacharjee S, Ghosh M, Biswas N, Chaudhuri U, Bandyopadhyay S.
    Apoptosis; 2009 Mar 28; 14(3):298-308. PubMed ID: 19153832
    [Abstract] [Full Text] [Related]

  • 16. Combination treatment of imatinib-sensitive and -resistant BCR-ABL-positive CML cells with imatinib and farnesyltransferase inhibitors.
    Radujkovic A, Topaly J, Fruehauf S, Zeller WJ.
    Anticancer Res; 2006 Mar 28; 26(3A):2169-77. PubMed ID: 16827161
    [Abstract] [Full Text] [Related]

  • 17. Effects of carboxyamidotriazole on in vitro models of imatinib-resistant chronic myeloid leukemia.
    Alessandro R, Fontana S, Giordano M, Corrado C, Colomba P, Flugy AM, Santoro A, Kohn EC, De Leo G.
    J Cell Physiol; 2008 Apr 28; 215(1):111-21. PubMed ID: 17924401
    [Abstract] [Full Text] [Related]

  • 18. The novel pyrrolo-1,5-benzoxazepine, PBOX-21, potentiates the apoptotic efficacy of STI571 (imatinib mesylate) in human chronic myeloid leukaemia cells.
    Bright SA, Greene LM, Greene TF, Campiani G, Butini S, Brindisi M, Lawler M, Meegan MJ, Williams DC, Zisterer DM.
    Biochem Pharmacol; 2009 Feb 01; 77(3):310-21. PubMed ID: 19014913
    [Abstract] [Full Text] [Related]

  • 19. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
    Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP, Auberger P.
    Oncogene; 2007 Apr 12; 26(17):2445-58. PubMed ID: 17043649
    [Abstract] [Full Text] [Related]

  • 20. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
    Kurosu T, Tsuji K, Kida A, Koyama T, Yamamoto M, Miura O.
    Oncogene; 2007 May 10; 26(21):2975-87. PubMed ID: 17130834
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.